表面电荷对阳离子基因载体的影响

阳离子基因载体表面带有大量正电荷,由于许多DNA和细胞膜表面带负电荷,因此阳离子基因载体表面电荷有利于提高结合DNA的效率,纳米粒子与细胞膜的吸附也受粒子表面电荷的影响。同时,其表面电荷也是产生细胞毒性的主要原因之一,因此揭示细胞毒性及其作用机制有利于开发出更安全高效的基因递送载体。本文综述了阳离子基因载体表面电荷对DNA结合能力、细胞摄入、转染效率以及细胞毒性及其作用机制的影响。     

阳离子脂质体介导RNA干扰的效果评价

考察自制的肽型阳离子脂质体CDO14作为RNA转染载体的细胞毒性及其运载si RNA进行RNA干扰的效果。通过MTT法检测脂质体对稳定表达荧光素酶的肺癌A549(Luc-A549)细胞的毒性。以脂质体为载体将荧光素酶si RNA(Luc-si RNA)转染至Luc-A549细胞内,用发光仪检测转染细胞内荧光素酶含量,BCA法检测细胞内总蛋白含量。在裸鼠腋下接种Luc-A549细胞,成瘤后尾静脉注射Luc-si RNA和脂质体的复合物,利用活体成像系统检测模型小鼠体内荧光素酶的表达量。细胞毒性实验表明,自制脂质体的毒性与商品脂质体DOTAP相近,低于商品脂质体Lipo2000;细胞转染实验表明自制脂质体作为基因转染载体的转染效率高于DOTAP;体内转染实验表明CDO14作为载体转染效果优于DOTAP。结果表明,肽型阳离子脂质体CDO14具有毒性小、转染效率高等优点,有望作为转染载体用于基因治疗。     

一种可降解的阳离子聚合物基因转染试剂

目的：合成一种高效、低毒的新型阳离子聚合物载体。方法：以低分子量的聚乙烯亚胺（PEI）为阳离子聚合物的基本单位,以可水解的2,4-戊二醇二丙烯酸盐（PODOA）为交联剂,合成高分子聚合物。用DNA凝胶迟滞实验验证聚合物与DNA的亲和力,以绿色荧光蛋白基因和萤光素酶检测其基因转染效率,用聚合物凝胶电泳实验鉴定其降解性,以MTT法检测其细胞毒性。结果：聚合物具有高的DNA结合亲和力、高基因转染效率,基因转染后的萤光素酶活性高达3×10^9RLU／mg,其基因转染效率相当于甚至优于目前市售的转染试剂,而细胞毒性明显低于其他试剂。该聚合物在中性环境下可降解,而在酸性条件下非常稳定。结论：合成的聚合物具有高转染效率和低细胞毒性,可能在转染和基因治疗研究中起重要作用。     

胆固醇嵌入式阳离子脂质体运载基因研究

阳离子脂质体是一种有临床应用潜力的抗肿瘤药物递药系统,助类脂能起到稳定双层膜和降低阳性成分毒性的作用,同时提供阳性类脂的细胞渗透功能。为了进一步发掘助类脂的应用潜力,该文采用胆固醇(cholesterol)作为助类脂制备阳离子脂质体,测定了脂质体的粒径及Zeta电位,脂质体的平均粒径为100~140 nm,Zeta电位为45~60 mV。脂质体分别与绿色荧光蛋白基因(pGFP-N2)、荧光素酶基因(pGL3)结合,形成脂质体/DNA复合物,通过载入人喉癌细胞(Hep-2),考察了其转染效率和细胞毒性。结果表明,阳离子类脂与胆固醇以1:1、1:2和1:4摩尔比例混合制备脂质体均能高效转染Hep-2细胞。毒性实验显示,阳离子类脂单独存在时对癌细胞具有一定的细胞毒性,随着胆固醇的加入,脂质体对细胞的毒性明显减小,与商品试剂DOTAP和Lipofectamine 2000相当。     

阳离子脂质体在转基因畜禽中的应用

脂质体是由可生物降解的磷脂组成的双分子层结构,与生物膜有较大的相似性和组织相容性.阳离子脂质体作为一种新型的基因转移载体,以其生产简便、毒性低、无感染危险等优点在转基因领域越来越受到研究人员的青睐.随着转基因动物研究的不断深入,阳离子脂质体更是成为当今各种转基因方法中首选的非病毒类外源基因载体,在保护外源基因和提高其转染效率方面都发挥着重要作用.就阳离子脂质体的结构形式、介导基因转移的机制及其目前在转基因畜禽领域中的研究进展做一综述.     

基于核酸自组装纳米结构的siRNA药物递送研究进展

RNA干扰(RNA interference,RNAi)作为转录后调节机制,可靶向mRNA进行剪切降解从而发挥基因沉默效应.siRNA (small interference RNA)因其高效性和特异性而被广泛应用于药物研究中.目前,研究者们已开发了多种阳离子载体用于siRNA递送.但由于siRNA双链结构具有相对较强的刚性结构,且阴离子电荷密度较低,无法与阳离子载体形成稳定、致密的复合物,使得siRNA的应用仍面临诸多挑战,如细胞摄取率低、靶向特异性差、递送过程不稳定、潜在的细胞毒性以及易诱发免疫反应等.近年来,核酸自组装纳米结构由于其结构灵活且负电荷密度较高而受到广泛关注,有望实现siRNA药物的高效递送和基因沉默.本文综述了近年来基于核酸自组装纳米结构的siRNA递送的研究进展及其应用.     

阳离子聚合物在非病毒基因转染中的研究进展

基因治疗为治疗先天性遗传疾病和严重后天获得性疾病提供了一条新途径.目前,基因载体分为两类:病毒载体和非病毒载体.病毒载体转染效率高,但由于某些病毒载体存在免疫原性、致癌性、宿主DNA插入整合等缺点,从而限制了它们的应用.非病毒载体具有价格低、制备简单、安全有效、无免疫原性等优点,成为基因载体研究的热点.阳离子多聚物是非病毒载体的典型代表.文中综述近年来阳离子多聚物作为基因载体的研究现状和进展,重点介绍了阳离子多聚物基因载体的分类和与DNA的相互作用和传递机制.     

阳离子脂质体及其在体内基因转染中的应用

阳离子脂质体已经成为基因转移使用最广泛的载体之一。本文从阳离子脂质体的理化特性、质粒／阳性子脂质复合体与生物大分子的相互作用、质粒／脂质复合体的基因转移机制等方面,对阳离子脂质体及其在体内基因转染中的应用进行了综述。     

猪肾细胞脂质磁转染系统的构建与表征

磁性纳米基因载体是一种非病毒基因载体,经过功能性基团修饰后能够连接阳离子转染剂构建细胞转染系统。本文将磁转染技术结合常用的脂质体转染,形成了一种新型动物体细胞转染方法,即称脂质磁转染(Liposomal magnetofection,LMF)。这将为体细胞克隆培育转基因动物提供稳定遗传的细胞系。为构建脂质磁性纳米基因载体复合物系统,本研究利用一种磁性纳米基因载体通过分子自组装与脂质阳离子转染剂结合,用于携带外源基因转染动物体细胞。通过原子力显微镜(AFM)观测、ζ电位-粒度等分析表征手段,研究磁性纳米基因载体的形貌、粒径分布、负载及浓缩DNA的方式。结果表明,通过猪肾(PK)细胞的LMF实验,与脂质体(Lipofectamine2000)介导的转染比较,具有较高的转染率,更重要的是克服了脂质体转染瞬时表达的缺陷。MTT细胞毒性试验结果也显示该方法具有较低的细胞毒性。因此LMF是一种切实可行的高效低毒性的细胞转染方法。     

新型可降解PEI衍生物的表征及其在Brl-3A细胞中的毒性和转染研究

目的:对新型可降解高分子进行表征,研究其在Brl-3A细胞中的毒性和转染效率,以及连接剂比例对以上方面的影响。方法:通过化学方法合成不同比例PEI-Tr高分子,考察其包裹质粒DNA形成纳米颗粒的粒径和电位,以CCK-8方法考察Brl-3A细胞中的细胞毒性,以荧光素酶质粒为报告基因考察Brl-3A细胞中的转染效率。结果:PEI-Tr材料能形成200 nm以下带20 mV左右正电荷的纳米颗粒,具有较好的细胞内吞能力和溶液稳定性,细胞毒性实验证明,随着浓度增加PEI-Tr材料显示了远低于PEI-25kDa的细胞毒性,细胞转染实验表明其拥有高效输送质粒的能力。结论:PEI-Tr是一种高效低毒的可降解聚阳离子载体,在基因输送领域有很大的潜力;连接剂的比例在聚阳离子功能中起到重要作用。     

Cationic nanocarriers induce cell necrosis through impairment of Na+/K+-ATPase and cause subsequent inflammatory response

Nanocarriers with positive surface charges are known for their toxicity which has limited their clinical applications. The mechanism underlying their toxicity, such as the induction of inflammatory response, remains largely unknown. In the present study we found that injection of cationic nanocarriers, including cationic liposomes, PEI, and chitosan, led to the rapid appearance of necrotic cells. Cell necrosis induced by cationic nanocarriers is dependent on their positive surface charges, but does not require RIP1 and Mlkl. Instead, intracellular Na⁺ overload was found to accompany the cell death. Depletion of Na⁺ in culture medium or pretreatment of cells with the Na⁺/K⁺-ATPase cation-binding site inhibitor ouabain, protected cells from cell necrosis. Moreover, treatment with cationic nanocarriers inhibited Na⁺/K⁺-ATPase activity both in vitro and in vivo. The computational simulation showed that cationic carriers could interact with cation-binding site of Na⁺/K⁺-ATPase. Mice pretreated with a small dose of ouabain showed improved survival after injection of a lethal dose of cationic nanocarriers. Further analyses suggest that cell necrosis induced by cationic nanocarriers and the resulting leakage of mitochondrial DNA could trigger severe inflammation in vivo, which is mediated by a pathway involving TLR9 and MyD88 signaling. Taken together, our results reveal a novel mechanism whereby cationic nanocarriers induce acute cell necrosis through the interaction with Na⁺/K⁺-ATPase, with the subsequent exposure of mitochondrial damage-associated molecular patterns as a key event that mediates the inflammatory responses. Our study has important implications for evaluating the biocompatibility of nanocarriers and designing better and safer ones for drug delivery.     

Recent advances in rational gene transfer vector design based on poly(ethylene imine) and its derivatives

The continually increasing wealth of knowledge about the role of genes involved in acquired or hereditary diseases renders the delivery of regulatory genes or nucleic acids into affected cells a potentially promising strategy. Apart from viral vectors, non-viral gene delivery systems have recently received increasing interest, due to safety concerns associated with insertional mutagenesis of retro-viral vectors. Especially cationic polymers may be particularly attractive for the delivery of nucleic acids, since they allow a vast synthetic modification of their structure enabling the investigation of structure-function relationships. Successful clinical application of synthetic polycations for gene delivery will depend primarily on three factors, namely (1) an enhancement of the transfection efficiency, (2) a reduction in toxicity and (3) an ability of the vectors to overcome numerous biological barriers after systemic or local administration. Among the polycations presently used for gene delivery, poly(ethylene imine), PEI, takes a prominent position, due to its potential for endosomal escape. PEI as well as derivatives of PEI currently under investigation for DNA and RNA delivery will be discussed.This review focuses on structure-function relationships and the physicochemical aspects of polyplexes which influence basic characteristics, such as complex formation, stability or in vitro cytotoxicity, to provide a basis for their application under in vivo conditions. Rational design of optimized polycations is an objective for further research and may provide the basis for a successful cationic polymer-based gene delivery system in the future.     

核酸自组装纳米递送载体的研究进展

随着核酸纳米技术的飞速发展,核酸自组装纳米载体已成为药物递送领域的研究热点。针对核酸自组装纳米载体在药物递送中的应用进展进行了系统综述,讨论了不同的核酸自组装策略,阐述了多种靶向递送和药物控制释放方法,同时,总结了核酸自组装纳米递送载体在蛋白质药物、核酸药物、小分子药物和纳米药物递送中的应用,并针对该领域的挑战和未来发展趋势进行了总结和展望,以期为药物递送领域和新型药物系统研究提供参考。     

siRNA纳米递送系统研究进展

小干扰RNA (small interfering RNA,siRNA)是RNA干扰的引发物,激发与之互补的目标mRNA沉默,对基因调控及疾病治疗有重要意义。siRNA作为药物需要克服血管屏障、实现细胞内吞及溶酶体逃逸,同时还需要避免核酸酶作用下发生降解。因此,设计合适的纳米载体以帮助siRNA成功递送进细胞并发挥作用是目前siRNA药物发展的重要目标。纳米载体的材料种类、尺寸、结构、表面修饰等精确设计是实现siRNA药物成功递送的重要因素。随着研究的深入和应用的发展,siRNA药物纳米载体的精确控制制备、精准靶向递送及多功能化取得了较好的成果。本文围绕siRNA药物纳米载体,对siRNA药物应用及其递送困难、siRNA药物纳米载体主要设计策略、目前siRNA药物上市情况进行介绍,同时对其未来发展方向进行展望。     

基于酸敏感的双响应抗癌药物载体的研究进展

为了达到更好的肿瘤治疗效果,研究者们针对肿瘤微环境设计出了双重和多重响应性智能纳米药物载体。其中基于酸敏感的双重响应性智能纳米药物载体的研究是最广泛、最常见的一种。在当前的研究中,该智能纳米药物载体已经初步实现了体内长循环、有效地抵达肿瘤细胞、在特定肿瘤微环境下控制药物释放等功效,增加了药物抗肿瘤疗效,有效地减少了药物对机体中正常组织的伤害。但是这类研究仍存在许多问题需要解决,如价格昂贵、载体结构复杂、体内药物传递机理不明确等,使其很难用于临床治疗。这里主要从酸-温度、酸-磁、酸-氧化还原、酸-酶、酸-光和酸-超声几个方面简单介绍了近几年的纳米载体研究进展,为进一步实现纳米药物临床应用奠定基础。     

新型非病毒三元复合DNA载体的研究

基因治疗是未来临床医学最具潜力的治疗方式,目前阻碍临床基因治疗发展的主要因素是缺乏安全和高效的基因载体,因此研究理想的非病毒转基因载体具有重要的意义.构建了由质粒DNA(D)-抗DNA抗体(A)-阳离子脂质体(C)组成的三元复合纳米基因载体(DAC),研究表明,三组分在磷酸缓冲液中可通过分子组装形成复合纳米胶束,DAC在细胞培养中表现出显著高效的基因表达,DAC在血管平滑肌细胞中的基因转染效率比不含抗DNA抗体的二元组合(DC)高4倍,比不含阳离子脂质体的二元组合(DA)约高11倍.激光共聚焦荧光显微观察证明,DAC细胞摄取量和DNA进入细胞核的量均明显高于对照组,而DC二元组合(不含抗DNA抗体)的DNA很少进入细胞核,细胞在DAC存在下生长正常.未发现细胞毒性.研究结果提示,DAC的作用机理主要是三元复合胶束中DNA的装载量比二元载体大得多,抗DNA抗体与阳离子脂质体的协同作用明显有利于DNA被细胞摄取和胞吞,从而提高了基因的转染和表达.     

Strategies for ocular siRNA delivery: Potential and limitations of non-viral nanocarriers

ABSTRACT: Controlling gene expression via small interfering RNA (siRNA) has opened the doors to a plethora of therapeutic possibilities, with many currently in the pipelines of drug development for various ocular diseases. Despite the potential of siRNA technologies, barriers to intracellular delivery significantly limit their clinical efficacy. However, recent progress in the field of drug delivery strongly suggests that targeted manipulation of gene expression via siRNA delivered through nanocarriers can have an enormous impact on improving therapeutic outcomes for ophthalmic applications. Particularly, synthetic nanocarriers have demonstrated their suitability as a customizable multifunctional platform for the targeted intracellular delivery of siRNA and other hydrophilic and hydrophobic drugs in ocular applications. We predict that synthetic nanocarriers will simultaneously increase drug bioavailability, while reducing side effects and the need for repeated intraocular injections. This review will discuss the recent advances in ocular siRNA delivery via non-viral nanocarriers and the potential and limitations of various strategies for the development of a 'universal' siRNA delivery system for clinical applications.     

Asialoglycoprotein receptor and liposome synergistically mediate the gene transfer into primary rat hepatocytes

Gene transfer into primary rat hepatocytes was performed by employing cationic liposome as DNA carrier and the specific ligand of hepatic asialoglycoprotein receptor (ASGPR), asialofetuin, as liver-targeting ligand. The resuits showed that asialofetuin, when added to the gene transfer complexes, could significantly increase the hepatocyte transfeetion efficiency, and alleviate the cellular toxicity of Lipofectin. Several synthetic ligands of ASGPR (galactosyl albumin) could also increase the transfection efficiency of hepatocyte like asialofetuin. It was proved that ASGPR and cationic liposome could synergistically mediate the gene transfer into primary rat hepatoeytes. This novel gene delivery system provided a safer, more simple and efficient gene transfer method for primary hepatocytes, and showed prospecting application in hepatic gene therapy.     

Successful transfection of hepatoma cells after encapsulation of plasmid DNA into negatively charged liposomes

The application of conventional cationic liposomes/DNA complexes in gene transfer was hampered due to their large size, instability, and limited transfection site in vivo. In this report, we described a dialysis-based method and produced small, stable, and negatively charged DNA-containing liposomes composed of low content of cationic lipid and high content of fusogenic lipid. The liposomes were relatively spherical with a condensed core inside, and exhibited small size with narrow particle size distribution. The encapsulation efficiency of the liposomes was 42.53 +/- 2.29%. They were stable and showed enough protective ability to plasmid DNA from degradation after incubation with different amounts of DNase. Twenty-fold higher transfection efficiency for the liposomes was achieved when compared with that of naked plasmid DNA and no toxicities to hepatocellular carcinoma cells were observed. Our results indicate that the negatively charged DNA-containing liposomes can facilitate gene transfer in cultured cells, and may alleviate the drawbacks of the conventional cationic liposomes/DNA complexes for gene delivery in vivo.